Uncategorized

By Jason N. Rosenbaum, MD, andDara L. Aisner, MD, PhD Posted: April 2018 Within the span of a few weeks, the U.S. Food and Drug Administration (FDA), the Center for Medicare and Medicaid Services (CMS), and the IASLC all issued guidelines, recommendations, or regulatory policy statements aimed at optimizing molecular testing for cancer.1-3 All three…

Posted: April 2018 Solange Peters, MD-PhD, PD-MER, runs the Thoracic Malignancies Program in the Department of Oncology at the University of Lausanne, Switzerland. Her main field of interest is new biomarker discovery and validation in preclinical/clinical settings, and she is also involved in developing multimodality trials for locally advanced NSCLC. She has been elected President…

Posted: April 2018 In January 2018, the response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) working group—an international collaboration of cancer treatment, scientific, and imaging experts— published a new guideline on addressing central nervous system (CNS) metastases in clinical trial designs for systemic agents.1 IASLC Lung Cancer News caught up with the guidelines’ lead author D.…

Posted: February 2018 Giorgio Vittorio Scagliotti, MD, Professor of Oncology at University of Torino and Head of the Department of Oncology and Chief of the Division of Medical Oncology at the San Luigi Hospital in Torino, Italy, earned his medical degree and completed his postgraduate training in respiratory medicine, internal medicine, and medical oncology at…

International sharing of best practices may improve quantitative imaging quality for low-dose CT for small nodules. By James L. Mulshine, MD Posted: February 2018 It is heartening to learn of the decision by thought leaders to begin the process of initiating European implementation of lung cancer screening.1 With this effort, the opportunity exists to off…

By Caicun Zhou, MD, and Fei Zhou, MD Posted: December 2017 Adjuvant chemotherapy is the standard of care for patients with resected, early-stage non–small cell lung cancer (NSCLC), including stage II, IIIA, and larger (≥4cm) IB tumors. The survival improvement observed with adjuvant chemotherapy is moderate, with a 5-year 5% absolute benefit. In an effort…

By Fabrice Barlesi, MD, PhD Posted: December 2017 Since the advent of adjuvant platinumbased chemotherapy as the standard of care, little progress has been achieved in significantly improving the cure rate of patients with resected early-stage lung cancer. However, attempts to biologically drive the postoperative management of these patients to provide more precise, more effective…

Posted: December 2017 How do you envision immunotherapy interdigitating in the adjuvant and neoadjuvant setting in resectable nonsmall cell lung cancer (NSCLC)? PACIFIC, which demonstrated a marked progression-free survival (PFS) advantage of 1 year of durvalumab after definitive concurrent chemoradiation in patients with unresectable NSCLC, gives us hope that this class of agents may likewise…

Posted: October 2017 The European Society for Medical Oncology (ESMO) has elected an emerging leader in thoracic oncology—and an IASLC board member—to lead the organization in 2020–2021. ESMO President- Elect Solange Peters, MD, PhD, is head of the medical oncology service and chair of thoracic oncology in the Oncology Department at the Centre Hospitalier Universitaire…

Posted: October 2017 When Margaret Foti began a job as an editorial assistant for the journal Cancer Research, with a communications degree and a fervor for the biological sciences, she could not have known then that she had just launched a remarkable, meaningful, and particularly impactful decades-long career. Just 4 years after her entry into…